Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD — Stella

Recruiting

Back to Graft vs Host Disease trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang

Key details

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

The First Affiliated Hospital of Zhengzhou University, Tongji Hospital

Enrollment target

~122 participants

Started

September 2025

Primary completion

September 2027

Age range

12 Years – 70 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov